Iguratimod: A new disease-modifying antirheumatic drug

Drugs of Today

Volumn 48, Issue 9, 2012, Pages 577-586

  Mucke, H A M ^a  

^a Pharma Consultancy   (Austria)

Author keywords

Cyclooxygenase 2; Cytokines; Disease modifying antirheumatic drugs; Immunoglobulin; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOOXYGENASE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; I KAPPA B ALPHA; IGURATIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; NIMESULIDE; PLACEBO; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; SULFONAMIDE;

ANALGESIC ACTIVITY; BONE METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RELEASE; DAILY LIFE ACTIVITY; DOSE CALCULATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HYPERTRANSAMINASEMIA; IC 50; IMMUNOGLOBULIN PRODUCTION; IN VIVO STUDY; INTERFERON PRODUCTION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; OSTEOCLASTOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TRANSIENT EXPRESSION; TREATMENT RESPONSE; ANIMAL; DRUG COMBINATION; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMONES; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; SULFASALAZINE; SULFONAMIDES;

EID: 84868636363     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.9.1855758     Document Type: Review

References (39)

1. Shuntaro, T., Chosaku, Y., Takihiro, I. et al. (Toyama Chemical Co., Ltd.). 4H-1-Benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient. US 4954518.
2. Inaba, T., Tanaka, K., Takeno, R., Nagaki, H., Yoshida, C., Takano, S. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull (Tokyo) 2000, 48(1): 131-9. (Pubitemid 30074953)
3. Tanaka, K., Shimotori, T., Makino, S., Aikawa, Y., Inaba, T., Yoshida, C., Takano, S. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: Antiinflammatory, analgesic and other related properties. Arzneimittelforschung 1992, 42(7): 935-44.
4. Tanaka, K., Makino, S., Shimotori, T., Aikawa, Y., Inaba, T., Yoshida, C. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7- methylsulfonylamino-6-phenoxy-4′-1-benzopyran-4-one. 2nd communication: Effect on the arachidonic acid cascades. Arzneimittelforschung 1992, 42(7): 945-50.
5. Tanaka, K., Shimotori, T., Makino, S., Eguchi, M., Asaoka, K., Kitamura, R., Yoshida, C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino- 6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: The involvement of bradykinin in its analgesic actions. J Pharmacobiodyn 1992, 15(11): 641-7. (Pubitemid 23026584)
6. Tanaka, K., Kawasaki, H., Kurata, K., Aikawa, Y., Tsukamoto, Y., Inaba, T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995, 67(4): 305-14.
7. Tanaka, K., Aikawa, Y., Kawasaki, H., Asaoka, K., Inaba, T., Yoshida, C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1- benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: Inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 1992, 15(11): 649-55. (Pubitemid 23026585)
8. Aikawa, Y., Tanuma, N., Kojima, T. et al. Suppressive effects of a new anti-rheumatic drug T-614 on TH1 and TH2 T cell-mediated autoimmune animal models. Arthritis Rheum 1996, 39 (Suppl.): S126.
9. Yamamoto, T., Konishi, Y., Mitamura, M., Aikawa, Y., Tanaka, K. Inhibition of immunoglobulin production by T-614, a new anti-rheumatic drug. Jpn J Pharmacol 1997, 73(Suppl. 1): Abst P-126.
10. Kohno, M., Aikawa, Y., Tsubouchi, Y. et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 2001, 28(12): 2591-6. (Pubitemid 33135640)
11. Aikawa, Y., Yamamoto, M., Yamamoto, T., Morimoto, K., Tanaka, K. An anti-rheumatic agent T-614 inhibits NFkappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 2002, 51(4): 188-94. (Pubitemid 34457532)
12. Shu, Q., Li, X.F., Hou, H.S., Li, D., Liu, H.X. Effect of T-614 on proliferation characteristics of fibroblast like synovial cells in osteoarthritis. Chin J Rheumatol 2006, 10 (7): 389-92.
13. Du F., Lü, L.J., Teng, J.L., Shen, N., Ye, P., Bao, C.D. T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol 2012, 13(1): 54-60.
14. Tanaka, K., Yamamoto, T., Aikawa, Y., Kizawa, K., Muramoto, K., Matsuno, H., Muraguchi, A. Inhibitory effects of an antirheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 2003, 42(11): 1365-71. (Pubitemid 37407028)
15. Tanaka, K., Yamamoto, T., Taniguchi, Y., Muramoto, K. Inhibition of immunoglobulin production by T-614 (Iguratimod), a novel DMARD, in cultured B cells and in animal models of arthritis. 68th Annu Sci Meet Am Coll Rheumatol (Oct 16-21, San Antonio) 2004, Abst 901.
16. Yamamoto, T. Immunopharmacological studies of a disease-modifying antirheumatic drug Iguratimod (T-614) - Its effect on immunoglobulin production and lymphocyte proliferation. Jpn Pharmacol Ther 2007, 35(6): 561-70.
17. Kawakami, A., Tsuboi, M., Urayama, S. et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999, 133(6): 566-74. (Pubitemid 29257219)
18. Yamamoto, M., Urata, N., Yamamoto, T., Aikawa, Y., Funaki, J., Tanaka, K. Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on inflammatory cytokine production. Jpn Pharmacol Ther 2007, 35(6): 551-9. (Pubitemid 47205195)
19. Murao, H., Omatsu, N., Aikawa, Y., Tanaka, K. Iguratimod, a disease-modifying antirheumatic drug, suppressed osteoclast differentiation in vitro. Int J Rheum Dis [13th Congr Asia Pacific League Assoc Rheumatol (APLAR) (Sept 23-27, Pacifico Yokohama) 2008] 2008, 11(Suppl. 1): A112.
20. Kuriyama, K., Higuchi, C., Tanaka, K., Yoshikawa, H., Itoh, K. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun 2002, 299(5): 903-9. (Pubitemid 36034572)
21. Murao, H., Mikami, M., Funaki, J., Muramoto, K., Tanaka, K. Iguratimod, a novel DMARD, inhibits osteoclastogenesis and bone resorption in vitro. Annu Eur Congr Rheumatol (EULAR) (June 6-9, 2012, Berlin) 2012, Abst AB0124.
22. Du, F., Lü, L.J., Fu, Q. et al. T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther 2008, 10(6): R136.
23. Aikawa, Y., Tanuma, N., Shin, T., Makino, S., Tanaka, K., Matsumoto, Y. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 1998, 89(1-2): 35-42. (Pubitemid 28389573)
24. Jiang, Y., Lü, W., Yu, S.Q., Yao, L., Xu, G.L., Zhang, X.R. Inhibitory effect of iguratimod on TNFalpha production and NF-kappaB activity in LPS-stimulated rat alveolar macrophage cell line. Yao Xue Xue Bao 2006, 41(5): 401-5. (Pubitemid 44022662)
25. Tanaka, K., Urata, N., Mikami, M., Ogasawara, M., Matsunaga, T., Terashima, N., Suzuki, H. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm Res 2007, 56(1): 17-23. (Pubitemid 46356225)
26. Chen, S.-Z., Guo, Y.-G. Combined use of iguratimod with pyrrolidine dithiocarbamate alleviates cancer cachexia in a mouse model. Chin J Exp Surg 2011, 28(5).
27. Xiao, F., Yang, Z.-Y., Yan, S.-X., Wei, W. Pharmacokinetic study of iguratimod in rats. Chin J Primary Med Pharm 2008, 15(6): 881-2.
28. Zhou, T., Ding, L., Li, X., Zhang, F., Zhang, Q., Gong, B., Guo, X. Determination of iguratimod in rat plasma by high performance liquid chromatography: Method and application. Biomed Chromatogr 2008, 22(3): 260-4. (Pubitemid 351459940)
29. Simcere Pharmaceuticals, 2012. Iremod product insert.
30. Hara, M., Kashiwazaki, S., Abe, T. et al. Therapeutic effect of T-614, a new anti-arthritic agent, on rheumatoid arthritis. Arthritis Rheum 1996, 39(Suppl. 9): S282.
31. Lü, L.-J., Teng, J.-L., Bao, C.-D. et al. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl) 2008, 121(7): 615-9.
32. Hara, M., Abe, T., Sugawara, S. et al. A phase III, double blind, comparative study to evaluate the efficacy and safety of T-614, a newly developed DMARD. Ann Rheum Dis [Annu Eur Congr Rheumatol (EULAR) (June 9-12, Berlin) 2004] 2004, 63(Suppl. 1): Abst OP0109.
33. Hara, M., Abe, T., Sugawara, S. et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: A controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 2007, 17(1): 1-9. (Pubitemid 46758763)
34. Lü, L.-J., Bao, C.-D., Dai, M. et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 2009, 61(7): 979-87.
35. Hara, M., Ishiguro, N., Katayama, K. et al. Efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent - A double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX. Annu Eur Cong Rheumatol (EULAR) (June 6-9, 2012, Berlin) 2012, Abst OP0205.
36. Ishiguro, N., Yamamoto, K., Katayama, K. et al. Iguratimod Clinical Study Group. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2012, Advance publication.
37. Hara, M., Abe, T., Sugawara, S. et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 2007, 17(1): 10-6. (Pubitemid 46758764)
38. A study of iguratimod in patients with active rheumatoid arthritis (NCT01554917). ClinicalTrials.gov Web site, accessed September 18, 2012.
39. Long-term efficacy of iguratimod alone or iguratimod in combination with methotrexate in patients with rheumatoid arthritis (NCT01548001). ClinicalTrials.gov Web site, accessed September 18, 2012.